Cytokines and chemokines in neuromyelitis optica: Pathogenetic and therapeutic implications

Brain Pathology

Volumn 24, Issue 1, 2014, Pages 67-73

  Uzawa, Akiyuki ^a   Masahiro, Mori ^a   Kuwabara, Satoshi ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

chemokine; cytokine; interleukin 17; interleukin 6; neuromyelitis optica; Th17

Indexed keywords

AZATHIOPRINE; CHEMOKINE; CORTICOSTEROID; CXCL13 CHEMOKINE; CYCLOPHOSPHAMIDE; CYTOKINE; EOTAXIN; EOTAXIN 2; EOTAXIN 3; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

CEREBROSPINAL FLUID ANALYSIS; CONFERENCE PAPER; DISEASE ACTIVITY; DISEASE MARKER; FEMALE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; LOW DRUG DOSE; MAINTENANCE THERAPY; MYELOOPTIC NEUROPATHY; NEUROPATHOLOGY; PLEIOTROPY; RECURRENCE RISK; REGULATORY T LYMPHOCYTE; TH17 CELL; TH2 CELL; TREATMENT INDICATION;

CHEMOKINE; CYTOKINE; INTERLEUKIN-17; INTERLEUKIN-6; NEUROMYELITIS OPTICA; TH17;

ANIMALS; ANTIBODIES; AQUAPORIN 4; CENTRAL NERVOUS SYSTEM; CHEMOKINES; CYTOKINES; HUMANS; NEUROMYELITIS OPTICA;

EID: 84890759137     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/bpa.12097     Document Type: Conference Paper

References (57)

1. Alvarez E, Piccio L, Mikesell RJ, Klawiter EC, Parks BJ, Naismith RT, Cross AH, (2013) CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Mult Scler 19: 1204-1208.
2. Alves-Leon SV, Pimentel ML, Sant'Anna G, Malfetano FR, Estrada CD, Quirico-Santos T, (2008) Immune system markers of neuroinflammation in patients with clinical diagnose of neuromyelitis optica. Arq Neuropsiquiatr 66: 678-684.
3. Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S, Yamamura T, (2013) Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 23: 827-831.
4. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, et al (2010) T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 16: 406-412.
5. Ayzenberg I, Kleiter I, Schröder A, Hellwig K, Chan A, Yamamura T, Gold R, (2013) Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 70: 394-397.
6. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al (2006) Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 441: 235-238.
7. Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, et al (2009) Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 66: 630-643.
8. Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T, et al (2011) Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 108: 3701-3706.
9. Correale J, Fiol M, (2004) Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology 63: 2363-2370. (Pubitemid 40024351)
10. Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, et al (2011) Azathioprine: tolerability, efficacy, and predictor of benefit in neuromyelitis optica. Neurology 77: 659-666.
11. Farina C, Aloisi F, Meinl E, (2007) Astrocytes are active players in cerebral innate immunity. Trends Immunol 28: 138-145. (Pubitemid 46283692)
12. Fujihara K, Misu T, Nakashima I, Takahashi T, Bradl M, Lassmann H, et al (2012) Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol 3: 58-73.
13. Herges K, de Jong BA, Kolkowitz I, Dunn C, Mandelbaum G, Ko RM, et al (2012) Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Mult Scler 18: 398-408.
14. Içöz S, Tüzün E, Kürtüncü M, Durmuş H, Mutlu M, Eraksoy M, Akman-Demir G, (2010) Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int J Neurosci 120: 71-75.
15. Ishizu T, Osoegawa M, Mei FJ, Kikuchi H, Tanaka M, Takakura Y, et al (2005) Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 128: 988-1002. (Pubitemid 40675455)
16. Ito S, Mori M, Makino T, Hayakawa S, Kuwabara S, (2009) "Cloud-like enhancement" is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol 66: 425-428.
17. Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, et al (2009) Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 66: 1128-1133.
18. Kaplin AI, Deshpande DM, Scott E, Krishnan C, Carmen JS, Shats I, et al (2005) IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Invest 115: 2731-2741. (Pubitemid 41434400)
19. Kieseier BC, Stüve O, Dehmel T, Goebels N, Leussink VI, Mausberg AK, et al (2013) Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol 70: 390-393.
20. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ, (2011) Repeated treatment with rituximab based on the assessment of peripheral circulating B cells in patients with relapsing neuromyeltis optica. Arch Neurol 68: 1412-1420.
21. Kim SH, Kim W, Park MS, Sohn EH, Li XF, Kim HJ, (2011) Efficacy and safety of mithoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol 68: 473-479.
22. Kinoshita M, Nakatsuji Y, Kimura T, Moriya M, Takata K, Okuno T, et al (2009) Neuromyelitis optica: passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun 386: 623-627.
23. Kishimoto T, (2005) Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 23: 1-21. (Pubitemid 40563163)
24. Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, et al, for the Neuromyelitis Optica Study Group (2012) Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 69: 239-245.
25. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR, (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202: 473-477. (Pubitemid 41186945)
26. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364: 2106-2112. (Pubitemid 39626806)
27. Li Y, Wang H, Long Y, Lu Z, Hu X, (2011) Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol 234: 155-160.
28. Linhares UC, Schiavoni PB, Barros PO, Kasahara TM, Teixeira B, Ferreira TB, et al (2013) The ex vivo production of IL-6 and IL-21 by CD4(+) T cells is directly associated with neurological disability in neuromyelitis optica patients. J Clin Immunol 33: 179-189.
29. Min JH, Kim BJ, Lee KH, (2012) Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 18: 113-115.
30. Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, Watanabe S, et al (2007) Loss of aquaporin-4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130: 1224-1234. (Pubitemid 47355951)
31. Narikawa K, Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y, (2004) CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis. J Neuroimmunol 149: 182-186. (Pubitemid 38352871)
32. Okada K, Matsushita T, Kira J, Tsuji S, (2010) B-cell activating factor of the TNF family is upregulated in neuromyelitis optica. Neurology 74: 177-178.
33. Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, Bruck W, et al (2007) Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 130: 1194-1205. (Pubitemid 47355941)
34. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC, (2010) Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133: 349-361.
35. Shimizu Y, Ota K, Kubo S, Kabasawa C, Kobayashi M, Ohashi T, Uchiyama S, (2011) Association of Th1/Th2-related chemokine receptors in peripheral T cells with disease activity in patients with multiple sclerosis and neuromyelitis optica. Eur Neurol 66: 91-97.
36. Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y, (2010) Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 75: 208-216.
37. Tanaka M, Matsushita T, Tateishi T, Ochi H, Kawano Y, Mei FJ, et al (2008) Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis. Neurology 71: 974-981.
38. Uzawa A, Mori M, Arai K, Sato Y, Hayakawa S, Masuda S, et al (2010) Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler 16: 1443-1452.
39. Uzawa A, Mori M, Hayakawa S, Masuda S, Kuwabara S, (2010) Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur J Neurol 17: 672-676.
40. Uzawa A, Mori M, Hayakawa S, Masuda S, Nomura F, Kuwabara S, (2010) Expression of chemokine receptors on peripheral blood lymphocytes in multiple sclerosis and neuromyelitis optica. BMC Neurol 10: 113.
41. Uzawa A, Mori M, Ito M, Uchida T, Hayakawa S, Masuda S, Kuwabara S, (2009) Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol 256: 2082-2084.
42. Uzawa A, Mori M, Masuda S, Kuwabara S, (2011) Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica. Arch Neurol 68: 913-917.
43. Uzawa A, Mori M, Masuda S, Muto M, Kuwabara S, (2013) CSF high-mobility group box 1 is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica. J Neurol Neurosurg Psychiatry 84: 517-522.
44. Uzawa A, Mori M, Sato Y, Masuda S, Kuwabara S, (2012) CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse. J Neurol Neurosurg Psychiatry 83: 339-340.
45. Uzawa A, Mori M, Sawai S, Masuda S, Muto M, Uchida T, et al (2013) Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clin Chim Acta 421: 181-183.
46. Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, Nelson PA, Stroud RM, Cree BA, Zamvil SS, (2012) Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol 72: 53-64.
47. Wang H, Wang K, Wang C, Xu F, Qiu W, Hu X, (2013) Increased plasma interleukin-32 expression in patients with neuromyelitis optica. J Clin Immunol 33: 666-670.
48. Wang H, Wang K, Wang C, Xu F, Zhong X, Qiu W, Hu X, (2013) Cerebrospinal fluid high-mobility group box protein 1 in neuromyelitis optica and multiple sclerosis. Neuroimmunomodulation 20: 113-118.
49. Wang H, Wang K, Zhong X, Dai Y, Qiu W, Wu A, Hu X, (2012) Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica. Neuroimmunomodulation 19: 304-308.
50. Wang HH, Dai YQ, Qiu W, Lu ZQ, Peng FH, Wang YG, et al (2011) Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci 18: 1313-1317.
51. Wang KC, Lee CL, Chen SY, Chen JC, Yang CW, Chen SJ, Tsai CP, (2013) Distinct serum cytokine profiles in neuromyelitis optica and multiple sclerosis. J Interferon Cytokine Res 33: 58-64.
52. Wang KC, Tsai CP, Lee CL, Chen SY, Chin LT, Chen SJ, (2012) Elevated plasma high-mobility group box 1 protein is a potential marker for neuromyelitis optica. Neuroscience 226: 510-516.
53. Watanabe S, Misu T, Miyazawa I, Nakashima I, Shiga Y, Fujihara K, Itoyama Y, (2007) Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 13: 968-974. (Pubitemid 351541430)
54. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG, (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66: 1485-1489. (Pubitemid 43958540)
55. Yanagawa K, Kawachi I, Toyoshima Y, Yokoseki A, Arakawa M, Hasegawa A, et al (2009) Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology 73: 1628-1637.
56. Zhang H, Bennett JL, Verkman AS, (2011) Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol 70: 943-954.
57. Zhong X, Wang H, Dai Y, Wu A, Bao J, Xu W, et al (2011) Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica. J Neuroimmunol 240-241: 104-108.